ReviewCancers2021
Effectiveness of Cell-Free and Concentrated Ascites Reinfusion Therapy in the Treatment of Malignancy-Related Ascites: A Systematic Review and Meta-Analysis.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Therapeutic effects of pleural and abdominal fluid filtration, concentration, and reinjection based on bioelectrical impedance analysis.Fujita medical journal · 2026Article
- CART for ascites accumulation and dialysis difficulty after hepatic cyst fenestration and bilateral nephrectomy in ADPKD: a case report.CEN case reports · 2026Article
- Usefulness of cell-free and concentrated pleural effusion reinfusion therapy in terminal cancer patients.Fujita medical journal · 2026Article
- Development of a Non-Contact Flow Sensor Based on a Permanent Magnet Metal Clip for Monitoring Circulation Status.Biosensors · 2026Article
- Cell-free and concentrated pleural effusion reinfusion therapy with aggressive nutritional support improved refractory pleural effusion in a patient with malnutrition after distal gastrectomy for gastric cancer.Fujita medical journal · 2025Article
- Novel Membrane Designed Polyether Sulfone Filter Reduces Filtration Membrane Obstruction Rate in Drop-Type With Adjustable Concentrator Cell-Free and Concentrated Ascites Reinfusion Therapy (DC-CART).Artificial organs · 2025Observational
- Contemporary Management of Malignant Ascites.The Journal of surgical research · 2025Review
- Cytokine dynamics and quality of life: unraveling the impact of cell-free and concentrated ascites reinfusion therapy in ovarian cancer patients.International journal of clinical oncology · 2025Article
- Drainage of ascites in cirrhosis.World journal of hepatology · 2024Review
- Combined Intraperitoneal Paclitaxel and Systemic Chemotherapy for Patients with Massive Malignant Ascites Secondary to Pancreatic Cancer: A Report of Two Patients.Internal medicine (Tokyo, Japan) · 2024Article
- The complex role of IL-10 in malignant ascites: a review.Cancer immunology, immunotherapy : CII · 2024Review
- Cell-free and concentrated ascites reinfusion therapy for refractory massive cardiac ascites in an adult with single ventricle haemodynamics: a case report.European heart journal. Case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignancy-related ascites (MRA) is one of the symptoms causing discomfort in advanced cancer patients. Cell-free and concentrated ascites reinfusion therapy (CART) is one of the palliative treatments widely conducted in Japan only.
methodsA systematic review following a meta-analysis of CART was performed. The efficiency and adverse events were evaluated.
resultsA total of 2567 patients and 6013 procedures of CART were identified in this study. The mean volume of MRA collected was 4.29 (95% confidence interval (CI) 3.47-5.11) L, and the volume reinfused after concentrating was 0.49 (95% CI 0.39-0.60) L. A total of 86.1 (95% CI 77.1-95.2) g protein and 42.9 (95% CI 36.0-50.0) g albumin was reinfused. The mean time to the next paracentesis was 20.7 (95% CI 15.6-25.8) days. The body weight was reduced by 3.38 (95% CI 1.90-4.86;
conclusionsCART might be a safe and effective palliative therapy in MRA and further clinical trials are necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.